The reference innovator product for JUPOKE^® Enalapril Maleate and Hydrochlorothiazide Tablets (Ⅰ) is Vaseretic, developed by Merck & Co., Inc. (MSD). As the world’s first approved fixed-dose combination antihypertensive drug consisting of an angiotensin-converting enzyme inhibitor (ACEI) and a diuretic, Vaseretic in the 10-25mg strength contains 10mg enalapril maleate and 25mg hydrochlorothiazide per tablet. It was approved for marketing by the U.S. Food and Drug Administration (FDA) in 1986.

• Better matches the tolerance profile of the Chinese population to diuretics

  Based on the physical characteristics of the Chinese population and clinical medication needs, and supported by clinical research data from top domestic clinical hospitals (including Shanghai Ruijin Hospital, Shanghai Huashan Hospital, Shanghai Changzheng Hospital, and West China Hospital of Sichuan University), we optimized and adjusted the dosage of hydrochlorothiazide while keeping the dosage of enalapril maleate in JUPOKE^® at 10mg. The content of hydrochlorothiazide per tablet was reduced to 6.25mg, which better matches the tolerance profile of the Chinese population to diuretics.

• More targeted treatment option for hypertensive patients in China

  The formulation with this dosage adjustment was approved by the National Medical Products Administration (NMPA) and classified as a Class II original new drug. It provides a more targeted treatment option for hypertensive patients in China.